ObjectiveTo investigate the protective effects of diisopropylamini dichlorocacetas on impairment of hepatic function in patients with sepsis. MethodsThe 60 inpatients with liver dysfunction and sepsis treated in our hospital between June 2010 and December 2012 were randomly divided into two groups: treatment group (n=30) and control group (n=30). In the treatment group, patients were treated with intravenous diisopropylamini dichlorocacetas for 7 days, while patients in the control group were treated with Vitamin C for the same period. The venous blood sample of each patient of the two groups was collected and examined for the content of alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, alkaline phosphatase, total bilirubin, and direct bilirubin before and after treatment, and the effective rates of the two groups were determined. ResultsLiver function indicators after treatment of both the two groups were reduced. Compared with the control group, the liver function indicators were significantly decreased and the total effective rate was significantly higher in the treatment group (P<0.05). ConclusionDiisopropylamini dichlorocacetas is effective in the treatment of impairment of hepatic function in patients with sepsis.
目的:分析原發性膽汁性肝硬化(PBC)患者的臨床表現,試驗室檢查及治療情況。方法:回顧性分析48例PBC患者臨床資料。結果:93.8%是中年女性患者,平均年齡53.2±8.73。主要的臨床表現包括肝功能異常(ALT、GGT、AKP升高)95.8%,乏力納差83.3%,黃疸79.2%,瘙癢66.6%,肝腫大62.5%,脾大58.3%等。常合并干燥綜合征(25%),類風濕關節炎(16.7%)等自身免疫性疾病及結締組織疾病。所以患者AMA及AMAM-2均為陽性。全部病例使用熊去氧膽酸治療,但僅31.3%患者病情有不同程度好轉。結論:加強對PBC的認識,重視對AMA 或AMA-M2的檢測,尤其對長期不明原因肝功能異常的女性患者。
目的:觀察前列地爾治療失代償期肝硬化的療效。方法:對2007年2月到2008年2月入院的失代償期肝硬化期肝硬化患者，按入院次序，查閱隨機數字表分為治療組和對照組，均給予支持、保肝、利尿治療，治療組加輸前列地爾100 μg+5%葡萄糖液250 mL，每日1次，療程2周。以治療前后ALT，AST，前白蛋白，24小時尿量，腹圍，B超下腹水深度為觀察指標。結果:治療2周后，治療組與對照組比較，AST，ALT，腹圍及腹水深度顯著下降，而前白蛋白及24小時尿量顯著升高。結論:前列地爾治療失代償期肝硬化療效顯著，副作用少。值得臨床推廣應用。